Literature DB >> 32502586

Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review.

Claire R Stewart1, Leah Algu2, Rakhshan Kamran3, Cameron F Leveille4, Khizar Abid2, Charlene Rae5, Shari R Lipner6.   

Abstract

BACKGROUND: Onychomycosis is the most common nail disorder, often causing physical, emotional, and aesthetic consequences. The effect of both the condition itself and treatment on quality of life has not been well studied.
OBJECTIVE: The objectives of this study were to systematically review the available literature describing the effect of onychomycosis and treatment on quality of life.
METHODS: We performed a search of the onychomycosis literature published before April 13, 2020. Articles were included in the review if primary data were presented, patient-reported outcome measures were used, and onychomycosis was specifically examined.
RESULTS: Thirty studies were included in the final analysis. Poorest quality-of-life scores were associated with women and fingernail involvement. Quality-of-life scores improved from baseline with all treatment types; there were greater improvements reported with oral treatments compared with topical ones.
CONCLUSIONS: This review affirms that onychomycosis significantly influences quality of life, warranting effective treatment. All treatments resulted in quality-of-life improvements; however, studies on oral and topical therapies were of higher quality than those evaluating devices. Increased efforts are needed to understand the effect of the disease and therapy as assessed by validated, nail-specific outcome measures that accurately assess patients' cosmetic, physical, and social difficulties.
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  amorolfine; ciclopirox; debridement; efinaconazole; itraconazole; laser therapy; nail fungus; onychomycosis; patient-reported outcome measures; photodynamic therapy; quality of life; terbinafine; topical therapy

Mesh:

Substances:

Year:  2020        PMID: 32502586     DOI: 10.1016/j.jaad.2020.05.143

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

Review 1.  Diagnosis of Onychomycosis: From Conventional Techniques and Dermoscopy to Artificial Intelligence.

Authors:  Sophie Soyeon Lim; Jungyoon Ohn; Je-Ho Mun
Journal:  Front Med (Lausanne)       Date:  2021-04-15

Review 2.  Optimal diagnosis and management of common nail disorders.

Authors:  Debra K Lee; Shari R Lipner
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

3.  Printing Drugs onto Nails for Effective Treatment of Onychomycosis.

Authors:  Thomas D Pollard; Margherita Bonetti; Adam Day; Simon Gaisford; Mine Orlu; Abdul W Basit; Sudaxshina Murdan; Alvaro Goyanes
Journal:  Pharmaceutics       Date:  2022-02-19       Impact factor: 6.321

Review 4.  Updated Perspectives on the Diagnosis and Management of Onychomycosis.

Authors:  Julianne M Falotico; Shari R Lipner
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-15

5.  More than Nail Deep: The Effect of Efinaconazole 10% Treatment on the Quality of Life in Patients with Onychomycosis: A post hoc Study.

Authors:  Aditya K Gupta; Maanasa Venkataraman; Emma M Quinlan; Madhulika A Gupta; Naveen Anbalagan; Rachel Lyons
Journal:  Skin Appendage Disord       Date:  2021-05-19

6.  Improving Transungual Permeation Study Design by Increased Bovine Hoof Membrane Thickness and Subsequent Infection.

Authors:  Sebastian Kappes; Thilo Faber; Lotta Nelleßen; Tanju Yesilkaya; Udo Bock; Alf Lamprecht
Journal:  Pharmaceutics       Date:  2021-12-06       Impact factor: 6.321

7.  The Success of Topical Treatment of Onychomycosis Seems to Be Influenced by Fungal Features.

Authors:  Vanessa Vasconcellos-Pontello; Flávia Franco Veiga; Marina Cristina Gadelha; Marielen Ribeiro; Melyssa Negri; Terezinha Inez Estivalet Svidzinski
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-09       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.